Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 5/2001

01-05-2001 | Original Research Article

The Lifetime Cost of Bipolar Disorder in the US

An Estimate for New Cases in 1998

Authors: Dr Charles E. Begley, John F. Annegers, Alan C. Swann, Christopher Lewis, Sharon Coan, William B. Schnapp, Lynda Bryant-Comstock

Published in: PharmacoEconomics | Issue 5/2001

Login to get access

Abstract

Objective: To develop a cost model that estimates the total and per case lifetime cost of bipolar disorder for 1998 incident cases in the US.
Study design: Lifetime cost simulation model.
Perspective: Societal.
Methods: Age- and gender-specific incidence of bipolar disorder in 1998 was estimated by simulation based on existing prevalence data. The course of illness and mental health service cost of 6 clinically defined prognostic groups was estimated based on the research literature and the judgement of panels of experts. Excess cost of general medical care was estimated based on claims data from a large insurer. Indirect cost was projected including excess unemployment and reduced earnings reported in the National Comorbidity Survey. Comorbidity treatment and indirect cost related to alcohol (ethanol) and drug abuse was added based on a National Institute on Drug Abuse study.
Results: The present value of the lifetime cost of persons with onset of bipolar disorder in 1998 was estimated at 24 billion US dollars ($US). Average cost per case ranged from $US11 720 for personswith a single manic episode to $US624 785 for persons with nonresponsive/chronic episodes.
Conclusion: The model indicates the potential cost savings of preventing a case of bipolar disorder and underscores the importance of achieving a stable outcome in new cases to limit the economic consequences of the disorder.
Literature
1.
Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness — 1991. Soc Psychiatry Psychiatr Epidemiol 1995; 30: 213–9PubMed
2.
Work Group on Bipolar Disorders. Practice guideline for treatment of patients with bipolar disorder. Am J Psych 1994; 151 (2): 139–208
3.
Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993; 54 (11): 405–18PubMed
4.
Hodgson TA. Costs of illness in cost-effectiveness analysis: a review of the methodology. Pharmacoeconomomics 1994; 6 (6): 536–52CrossRef
5.
Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8–19PubMedCrossRef
6.
Harwood H, Fountain D, Livermore G. The economic costs of alcohol and drug abuse in the United States, 1992. Bethesda (MD): U.S Dept of Health and Human Services, National Institute on Drug Abuse, National Institute on Alcohol Abuse and Alcoholism, 1998
7.
Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Q 1982; 60: 429–62
8.
Regier DA, Myers JK, Kramer M, et al. The NIMH Epidemiologic Catchment Area program: historical context, major objectives, and study population characteristics. Arch Gen Psychiatry 1984; 41: 934–41PubMedCrossRef
9.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd rev. ed. Washington, DC: American Psychiatric Association, 1987
10.
Joyce PR. Age of onset in bipolar affective disorder and misdiagnosis as schizophrenia. Psychol Med 1984; 14: 145–9PubMedCrossRef
11.
Loranger AW, Levine PM. Age at onset of bipolar affective illness. Arch Gen Psychiatry 1978; 35: 1345–8PubMedCrossRef
12.
Burke KC, Burke Jr JD, Regier DA, et al. Age at onset of selected mental disorders in five community populations. Arch Gen Psychiatry 1990; 47: 511–8PubMedCrossRef
13.
Boyd JH, Weissman MM. Epidemiology of affective disorders: A reexamination and future directions. Arch Gen Psychiatry 1981; 38: 1039–46PubMedCrossRef
14.
Rasanen P, Tiihonen J, Hakko H. The incidence and onset-age of hospitalized bipolar affective disorder in Finland. J Affect Disord 1998; 48: 63–8PubMedCrossRef
15.
Spicer CC, Hare EH, Slater E. Neurotic and psychotic forms of depressive illness: evidence from age-incidence in a national sample. Br J Psychiatry 1973; 123: 535–41PubMedCrossRef
16.
Hilty DM, Brady KT, Hales RE. A review of bipolar disorder among adults. Psychiatr Serv 1999; 50 (2): 201–13PubMed
17.
Unutzer J, Simon G, Pabiniak C, et al. The treated prevalence of bipolar disorder in a large staff-model HMO. Psychiatr Serv 1998; 49: 1072–8PubMed
18.
Gitlin MJ, Swendsen J, Heller T, et al. Relapse and impairment in bipolar disorder. Am J Psychiatry 1995; 152: 1635–40PubMed
19.
Harrow M, Goldberg JF, Grossman LS, et al. Outcome in manic disorders: a naturalistic follow-up study. Arch Gen Psychiatry 1990; 47: 665–71PubMedCrossRef
20.
Goldberg JF, Harrow M, Leon AC. Lithium treatment of bipolar affective disorders under naturalistic followup conditions. Psychopharmacol Bull 1996; 32: 47–54PubMed
21.
Goldberg JF, Harrow M, Grossman LS. Course and outcome in bipolar affective disorder: a longitudinal follow-up study. Am J Psychiatry 1995; 152: 379–84PubMed
22.
Maj M, Pirozzi R, Magliano L. Late non-response to lithium prophylaxis in bipolar patients: prevalence and predictors. J Affect Disord 1996; 39: 39–42PubMedCrossRef
23.
Maj M, Pirozzi R, Kemali D. Long-term outcome of lithium prophylaxis in patients initially classified as complete responders. Psychopharmacology (Berl) 1989; 98: 535–8CrossRef
24.
Tohen M, Waternaux CM, Tsuang MT, et al. Four-year follow-up of twenty-four first-episode manic patients. J Affect Disord 1990; 19: 79–86PubMedCrossRef
25.
Armond AD. The social and economic effects of manic depressive illness and of its treatment in lithium clinics. Occup Med 1998; 48: 505–9CrossRef
26.
Berghofer A, Kossmann B, Muller Oerlinghausen B. Course of illness and pattern of recurrences in patients with affective disorders during long-term lithium prophylaxis: a retrospective analysis over 15 years. Acta Psychiatr Scand 1996; 93: 349–54PubMedCrossRef
27.
Maj M, Pirozzi R, Magliano L, et al. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998; 155: 30–5PubMed
28.
Coryell W, Endicott J, Keller M. Outcome of patients with chronic affective disorder: a five-year follow-up. Am J Psychiatry 1990; 147: 1627–33PubMed
29.
Simon GE, Unutzer J. Health care utilization and costs among patients treated for bipolar disorder in an insured population. Psychiatr Serv 1999; 50 (10): 1303–8PubMed
30.
Kessler RC, Zhao S, Katz SJ, et al. Post-year use of outpatient services in the National Comorbidity Study. Am J Psychiatry 1999; 156 (1): 115–23PubMed
31.
GlaxoWellcome. Healthcare resource utilization and expenditure associated with the diagnosis of bipolar disorder. Raleigh (NC): GlaxoWellcome, Global Health Outcomes, 1999 Sep
32.
Chen YW, Dilsaver SC. Lifetime rates of suicide attempts among subjects with bipolar and unipolar disorders relative to subjects with other Axis I disorders. Biol Psychiatry 1996; 39: 896–9PubMedCrossRef
33.
Weeke A, Vaeth M. Excess mortality of bipolar and unipolar manic-depressive patients. J Affect Disord 1998; 11: 227–34CrossRef
34.
Metadata
Title
The Lifetime Cost of Bipolar Disorder in the US
An Estimate for New Cases in 1998
Authors
Dr Charles E. Begley
John F. Annegers
Alan C. Swann
Christopher Lewis
Sharon Coan
William B. Schnapp
Lynda Bryant-Comstock
Publication date
01-05-2001
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 5/2001
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200119050-00004

Other articles of this Issue 5/2001

PharmacoEconomics 5/2001 Go to the issue

Original Research Article

Economic Evaluation of a New Acellular Vaccine for Pertussis in Canada

Current Opinion

Lifestyle Drugs

Original Research Article

The Cost Effectiveness of Tapered versus Abrupt Discontinuation of Oral Cyclosporin Microemulsion for the Treatment of Psoriasis

Original Research Article

The Cost of Inadequate Prescriptions for Hypolipidaemic Drugs

Review Article

Hip Fracture Prevention

Original Research Article

Cost Effectiveness of Nasal Calcitonin in Postmenopausal Women